EP0611375A1 - Peptides inhibant la liberation d'il-1 beta - Google Patents

Peptides inhibant la liberation d'il-1 beta

Info

Publication number
EP0611375A1
EP0611375A1 EP92922580A EP92922580A EP0611375A1 EP 0611375 A1 EP0611375 A1 EP 0611375A1 EP 92922580 A EP92922580 A EP 92922580A EP 92922580 A EP92922580 A EP 92922580A EP 0611375 A1 EP0611375 A1 EP 0611375A1
Authority
EP
European Patent Office
Prior art keywords
formula
radical
compound
amino
alkyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP92922580A
Other languages
German (de)
English (en)
Inventor
Richard Heng
Trevor Glyn Payne
Laszlo Revesz
Beat Weidmann
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novartis Pharma GmbH
Sandoz AG
Original Assignee
Sandoz Erfindungen Verwaltungs GmbH
Sandoz AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sandoz Erfindungen Verwaltungs GmbH, Sandoz AG filed Critical Sandoz Erfindungen Verwaltungs GmbH
Publication of EP0611375A1 publication Critical patent/EP0611375A1/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/02—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link
    • C07K5/0202—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link containing the structure -NH-X-X-C(=0)-, X being an optionally substituted carbon atom or a heteroatom, e.g. beta-amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/545—IL-1
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06008—Dipeptides with the first amino acid being neutral
    • C07K5/06017—Dipeptides with the first amino acid being neutral and aliphatic
    • C07K5/06034—Dipeptides with the first amino acid being neutral and aliphatic the side chain containing 2 to 4 carbon atoms
    • C07K5/06052—Val-amino acid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08—Tripeptides
    • C07K5/0802—Tripeptides with the first amino acid being neutral
    • C07K5/0804—Tripeptides with the first amino acid being neutral and aliphatic
    • C07K5/0808—Tripeptides with the first amino acid being neutral and aliphatic the side chain containing 2 to 4 carbon atoms, e.g. Val, Ile, Leu
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Definitions

  • the present invention relates to peptides having pharmaceutical utility, processes for their production, pharmaceutical compo-sitions comprising them and their use as pharmaceuticals.
  • R is hydrogen, an amino protecting group or optionally ring substituted benzyloxy
  • a 1 is Val, Leu, Ala, lie or trimethylsilyl-Ala
  • a 2 is Phe or Tyr
  • n 0 or 1
  • a 3 is a direct bond, Val, Leu, Ala, lie, trimethylsilyl-Ala or a divalent radical of formula (a)
  • vherein ring A is optionally substituted by hydroxy or
  • C 1-4 alkoxy is a direct bond or a divalent radical of formula (b) wherein R 1 is hydrogen or C 1-4 alkyl, and
  • Y 1 is the residue attaching to the ⁇ -carbon atom of an ⁇ -amino acid and optionally protected, -CH 2 -CH 2 -N(C 1-4 alkyl) 2 , imidazol-2-yl-methyl, benzimidazol-2-yl-methyl, 1H-1,2,4-triazol-3-yl- methyl, pyrazol-3-yl-methyl, indazol-3-yl-methyl or a radical of formula (c) or (d)
  • each of R 2 and R 3 independently, is hydrogen
  • each of R 4 and R 5 independently is hydrogen
  • R 6 is H or C 1-4 alkyl
  • a 5 is hydrogen; CF 3 ; a radical -Z 1 -Z 2 -Y 2 wherein each of Z 1 and Z 2 independently is a direct bond or an ⁇ -amino acid residue and Y 2 is NH 2 , C 1-4 alkylamino, di-(C 1-4 alkyl)amino or a heterocyclic radical attached by a nitrogen to Z 2 ; a radical -CH 2 -X 1 -Y 3 wherein X 1 is O or S and Y 3 is heteroaryl; a radical -CH 2 -Y3; or a radical of formulae (k) to (m)
  • Y 4 is tri-(C 1-4 alkyl)methyl or a residue ring B is pyridyl
  • - ring C is phenyl or pyridyl
  • each of R 7 and R 8 independently is C 1-4 alkyl, C 1-4 alkoxy,
  • each of R 9 , R 10 and R 11 independently is nitro, cyano,
  • R 12 is C 1-6 alkyl
  • X is a divalent radical of formula (f) ,
  • a 5 is -Z 1 -Z 2 -Y 2 or a radical of formulae (k) to (o) as defined above, or OR 13 or NR 14 R 15 wherein R 13 is C 1-12 al- kyl optionally substituted by OH or interrupted by 0 and each of R 14 and R 15 is independently hydrogen, C 1-12 al- kyl, C 5-7 cycloalkyl or benzyl, or
  • X is a divalent radical of formula (g)
  • a 5 is -Z 1 -Z 2 -Y 2 as defined above, or
  • X is a divalent radical of formula (h) or (j)
  • a 5 is a radical of formulae (k) to (o), -CH 2 -Y 3 or
  • a 3 and A 4 can be a direct bond when n is 0, and each of A 3 and A 4 is other than a direct bond when n is 1. and the physiologically-hydrolysable and -acceptable esters or amides thereof, in free form, in salt form or in the form of complexes.
  • protecting groups as R are e.g. disclosed in "Protective Groups in Organic Synthesis", T. W. Greene, J.Wiley & Sons NY (1981), 219-287, for example acyl such as acetyl, methoxysuccinyl, hydroxysuccinyl or benzoyl optionally substituted on the phenyl ring with e.g.
  • p-methoxycarbonyl p-methoxy or p-nitro
  • alkoxycarbonyl such as t-butyloxycarbonyl
  • arylmetho ⁇ xycarbonyl such as 9-fluorenylmethoxycarbonyl or benzyloxy carbonyl optionally substituted on the phenyl ring with p-methoxy, p-nitro, p-chloro or m-phenyl
  • arylmethyl such as benzyl optionally ring substituted with p-methoxy, p-nitro or p-chloro
  • arylsulfonyl such as phenylsulfonyl optionally ring substituted with p-methyl or p-methoxy, or naphthylsulfonyl optionally ring substituted with e.g. amino or di(C 1-4 alkyl)amino.
  • R is ring substituted benzyloxy, it is preferably benzyloxy substituted with hydroxy or C 1-4 alkoxy.
  • R is
  • Halogen is preferably fluorine or chlorine.
  • ⁇ -amino acid is meant a naturally occurring or commercially available or non natural ⁇ -amino acid or an optical isomer thereof.
  • a non natural ⁇ -amino acid is an ⁇ -amino acid which is not incorporated into a protein under mRNA direction, e.g. ⁇ -Nal, a fluoro- ⁇ -amino acid such as fluoroalanine, trimethylsilyl-Ala or an ⁇ -amino acid such as
  • n 1 is an integer from 1 to 6 and n 2 is an integer from 1 to 12.
  • Protecting groups which may be present in Y 1 are groups which protect the O, S or N functionality in the side chain amino groups of an ⁇ -amino acid.
  • N-protecti ⁇ g groups are e.g. as disclosed above for R, or C 3-5 alkyl such as isopropyl, formyl, a sugar residue such as 1-deoxy-fructosyl or ⁇ -glucosyl(1-4)- deoxyfructosyl, dihydroxy-C 3-6 alkyl such as dihydroxypropyl, C 5-7 cycloalkyl such as cyclohexyl or tropinyl.
  • S-protecting groups for hydroxy and thiol functionalities are known and may be e.g. methyl, t.-butyl or benzyl.
  • Y 2 is a heterocyclic radical, it may be e.g. a 5 or 6 membered ring, e.g. piperidino or pyrrolidinyl.
  • heteroaryl as Y 3 examples include e.g. 5-, 6- or 7-membered unsaturated heterocyclic radicals, comprising at least one nitrogen and optionally further heteroatoms such as N, O or S.
  • Y 3 is heteroaryl comprising from 1 to 4 nitrogen atoms, e.g. pyridyl, triazolyl, tetrazolyl, triazin-dionyl.
  • ring B of radical (o) the nitrogen atom may be in o-, m- or para.
  • ring C in radical (k) is pyridyl, it may be 3-, 4- or 5-pyridyl.
  • Radicals (e 1 ), (e 2 ), (f), (g) and (j) are derived from Asp and comprise one asymetric carbon atom and radical (h) comprises two asymetric carbon atoms and accordingly they lead to optical isomerism. It will be understood that the present invention includes all individual isomeric forms and diastereoisomers as well as mixtures, e.g. racemates, unless otherwise stated.
  • Radical of formula (e 1 ) attached to A 5 which is hydrogen may exist in both cyclic as well as in non-cyclic form e.g. as follows:
  • the present invention embraces both lactol and oxo-carboxylic acid forms, i.e. although compounds of formula I wherein X is a radical of formula (e 1 ) are defined for convenience by reference to the oxo-carboxylic acid form only, the invention is not to be understood as being in any way limited by the particular nomenclature or graphic representation employed. Similar considerations apply in relation to starting materials exhibiting lactol/oxo-carboxylic acid tautomerism as hereinafter described.
  • radical of formula (h) which may exist in both linear and cyclic form as follows:
  • esters and amides which are hydrolysable under physiological conditions to yield alcohols or amines which are themselves physiologically acceptable, i.e. which are non-toxic at the desired dosage levels.
  • esters or amides are obtained by esterification or
  • esters include esters with an aliphatic or alicyclic alcohol or polyol having 1 to 12 carbon atoms.
  • amides include amides with aliphatic amines, e.g. C 1-4 alkyl amine, C 1-4 alkoxy-C 1-4 alkyl amine such as ⁇ -methoxy-ethyl amine, or aniline.
  • the compounds of formula I may exist e.g. in free form, acid addition salt form or in the form of complexes thereof.
  • Acid addition salts may be formed with e.g. organic acids, polymeric acids and inorganic acids. Such acid addition salt forms include e.g. the hydrochlorides and acetates. Salt forms may also include those obtainable with the carboxylic group present in compounds of formula I, e.g. alkali metal salts such as sodium or potassium, or substituted or unsubstituted ammonium salts.
  • Complexes are e.g. formed from compounds of formula I on addition of inorganic substances, e.g. inorganic salts or hydroxides such as Ca-and Zn-salts, and/or an addition of polymeric organic substances.
  • R is an amino protecting group or benzyloxy, preferably an amino protecting group.
  • R is preferably benzyloxy when n is 0 and A 3 is a radical of formula (a).
  • Each of A 3 and A 4 are other than a direct bond.
  • a 3 is a radical of formula (a) when n is 0.
  • a 3 is a direct bond, Val, Leu, Ala, lie or trimethylsily-Ala.
  • R 1 is hydrogen or methyl, preferably hydrogen.
  • Y 1 is the residue attaching to the ⁇ -carbon atom of an ⁇ -amino acid selected from Ala, Leu, His, Phe, Met, Trp,
  • Y 1 is a radical of formula (c). 8.
  • a 3 and A 4 may also form together a radical of formula (aa) when n is O.
  • m is 2 or 3.
  • X is a radical of formula (e 1 ) and A 5 is other than H.
  • X is a radical of formula (g).
  • X is a radical of formula (h) or (j).
  • R 6 is hydrogen or methyl, preferahly hydrogen.
  • Z 1 in A 5 is the residue of a natural ⁇ -amino acid, preferably of an aromatic/heterocyclic ⁇ -amino acid, particularly Pro.
  • Z 2 in A 5 is the residue of a natural ⁇ -amino acid, preferably an aliphatic ⁇ -amino acid, particularly an aliphatic ⁇ -amino acid without further functional group, most preferably Val.
  • X is a radical of formula (e 1 ) optionally esterified or
  • a 5 is a radical of formula (k), (1) or (o).
  • X is a radical of formula (e 1 ), (h) or j(j) optionally esterified or amidated and A 5 is -CH 2 -X 1 -Y 3 , preferably
  • X is a radical of formula (h) or (j) optionally esterified or amidated and A 5 is (k.).
  • X is a radical of formula (j) optionally esterified or
  • a 5 is a radical of formula (m).
  • Radical of formula (m) is monosubstituted, preferably in para, more preferably it is 4-nitrophenyl.
  • X has the D or L configuration.
  • the asymetric carbon in (j) bearing R 6 has the configuration R.
  • the present invention also provides a compound of formula I wherein
  • a 3 is a direct bond, Val, Leu, Ala, lie or trimethylsilyl-Ala,
  • a 4 is as defined above, or A 3 and A 4 form together a radical of formula (aa) as defined above, and
  • X is a radical of formula (e 1 ) or (e 2 ) as defined above and
  • a 5 is H, or
  • X is a radical of formula (e 1 ) or (f) and A 5 is -Z 1 -Z 2 -Y 2 as defined above or a radical of formula (k), (l) or (m) wherein
  • iii)X is a radical of formula (g) and A 5 is -Z 1 -Z 2 -Y 2 , or iv) X is a radical of formula (j) and A 5 is a radical of formula
  • the present invention also provides a process for the production of a compound of formula I, which process comprises: a) removing at least one protecting group from a compound of formula I in protected form or adding a protecting group R at the N-terminal group of a compound of formula I; or b) converting one compound of formula I into another compound of formula I; or c) coupling together by an amide bond two peptide fragments, each of which contains at least one amino acid in protected or unprotected form and one peptide fragment containing a radical of formula (e 1 ) to (j) as defined above, the peptide fragments being such that a protected or unprotected peptide having the sequence according to formula I above is obtained and, if necessary, removing the protecting group or groups from a compound of formula I in protected form; or d) for the production of a compound of formula I wherein X is a radical of formula (e 1 ) or (h) and A 5 is a radical of formula (k), (l) or (o) or -
  • R-[A 1 -A 2 ] n -A 3 -A 4 -X'-CH 2 -Z a (III) wherein R, A 1 to A 4 and n are as defined above, X' is a radical of formula (e 1 ) or (h), and Z a is a leaving group, e.g. halogen, with a corresponding phenol, thiophenol or HX 1 -pyridine or an acid of formula HX 1 -CO-Y 4 or a functional derivative thereof or HX 1 -Y 3 ; or e) for the production of a compound of formula I
  • R, A 1 to A 5 and n are as defined above and R 16 is a C 1-12 aliphatic or alicyclic residue, oxidizing a compound of formula V
  • R, A 1 to A 5 , n and R 1 6 are as defined above, and recovering a compound of formula I thus obtained in free or salt form or in the form of a complex.
  • Processes (a) to (e) above may be carried out in accordance with standard techniques known in the art.
  • the removal of a protecting group in process step (a) may also include the removal of R on the N-terminal group of a compound of formula I.
  • R is benzyloxy carbonyl
  • this group may be removed by hydrogenation in the presence of a catalyst, e.g. Pd.
  • a compound of formula I wherein X comprises a carboxy group may be hydrolysed.
  • Suchhydrolysis may be effected by treatment with an appropriate alkali or by acid hydrolysis, for example in the presence of trifluoroacetic acid.
  • a compound of formula I wherein X comprises a carboxy group or an esterified caboxy group may be (trans) esterified or amidated.
  • ester formation or amidation may be carried out using any of the techniques known in the art, for example converting the carboxy group in a functional reactive group, e.g. a corresponding carbonyl halide or anhydri- de, or using a compound of formula I wherein X is a radical of formula (h) in the lactone form, and reacting such group with the selected alcohol or amine.
  • a compound of formula I wherein X is a radical of formula (g) for the production of a compound of formula I wherein X is a radical of formula (g), a compound of formula I wherein X is a radical of formula (e 1 ) or (e 2 ) and A 5 is H may be reacted with a compound of formula II
  • a compound of formula I wherein X is a radical of formula (e 1 ) may also be converted in accordance with known techniques into a compound of formula I wherein X is a radical of formula (e 2 ) and vice versa.
  • Process step (c) may be carried out by the techniques known in the art of peptide chemistry.
  • peptide fragment comprising a radical of formula (e 1 ) to (j) is also meant the radical itself bearing a protecting group on the -NR 6 - moiety and an appropriate ending, e.g. A 5 or CH 2 -Z a , on the other end.
  • Process step (d) may conveniently be effected using a Dess-Martin reagent, e.g. in the presence of a base or a halogen-precipita-ting silver salt, or according to the Swern oxidation procedures.
  • a Dess-Martin reagent e.g. in the presence of a base or a halogen-precipita-ting silver salt, or according to the Swern oxidation procedures.
  • protecting groups may be used for functional groups which do not participate in the reaction. These may be e.g. amino protecting groups, carboxy protecting groups, acetal groups etc. When the desired reaction is complete, the protecting groups may then be removed.
  • each of the above processes may be carried out using starting materials in the form of one or other of the individual optical isomers or in the form of mixtures [relating to the asymetric carbons present in radicals of formulae (e 1 ) to (j) as X or in such a radical precursor].
  • the starting materials are used as S- or R-enantiomers to produce a compound of formula I wherein the asymetric carbon in radicals of formulae (ei) to (j) has the S or R configuration, respectively.
  • Example 4 Z-Val-Phe-Asp(OH)-H
  • Example 5 Z-Val-His-Asp( OH) -H
  • a 3 , A 4 and A 5 are as defined below, may be prepared.
  • the (3R,4RS) derivative of the title compound may be prepared as follows:
  • a 3 , A 4 , R x and R y are as defined below, may be prepared.
  • Triethylamine (1.3 ml, 9.6 mmol), followed be ethylchloroformiate (0.92 ml, 9.6 mmol) are added to (3S)-3-(fluorenylmethoxycarbo-nyl)amino-3-carboxy-butanoic acid tert. butyl ester (3.5 g, 8.5 mmol) in THF (60 ml) at - 10 °. After 10 min., a solution of dia-zomethane in ether is added slowly, and the reaction mixture stirred for 45 min. at 0 - 5 °. HCl (2N) in ether is added at 5 -10 ° until gas evolution has ceased.
  • reaction mixture is eva-porated to dryness, taken up in acetone (50 ml) Nal (4 g) added and stirred for 1 hr at r.t. Ether (150 ml) is added, the reaction mixture filtered and evaporated. The residue is chromatographed (SiO 2 , EtOAc/hexane), yielding the title compound as slightly yellow crystals.
  • EXAMPLE 70 (3S)-3-(Fluorenylmethoxycarbonyl)amino-5(2,6- difflethylbenzoyloxy)-4-oxo pentanoic acid tert.butyl ester
  • compounds of the invention exhibit pharmaceutical activity and are, therefore, useful as pharmaceuticals.
  • the compounds of the invention inhibit IL-1 ⁇ secretion as indicated in the following in vitro test using THP-1 cells and in vivo test methods: a) 900 ⁇ l THP-1 cells (0.5 ⁇ 10 6 cells) together with 100 U
  • L-glutamine and 5 % heat-inactivated foetal calf serum are pipetted into 24 well culture plates. 100 ⁇ l of the compound to be tested are then added. After 3 hours at 37 ° C in 5 % CO 2 /95 % air, 10 ⁇ l lipopolysaccharide 500 ⁇ g/ml is added and the incubation continued for a further 40 hours. Appropriate controls (with and without stimulus, solvent) ar also included. The media are then removed and clarified by centrifugation at 1000 g for 10 min. 1.0 ml digitonin 0.01 % is added to the wells to lyse the cells which are loosened by scraping with a rubber policeman and left at 4 ° C for 10 min.
  • Lactate dehydrogenase measurements are then performed immediately and the samples stored at - 20 ° C until the other determinations can be made.
  • the assays are: IL-1 ⁇ (medium and lysate), IL-6 (medium), TNF- ⁇ (medium), PGE2 (medium and lysate), lactate dehydrogenase (LDH) and DNA (lysates).
  • IL-1 ⁇ , IL-6 and TNF- ⁇ assays are determined using commercially available ELISA kits (Cistron), PGE 2 is measured using a standard RIA and DNA fluorimetrically using DAPI.
  • the compounds of the invention selectively inhibit IL-1 ⁇ release in concentrations from about 0.01 to 100 ⁇ M.
  • IL-6, TNF- ⁇ , PGE2 and DNA levels remain substantially unaffected, and the compounds are non-toxic, since LDH release is unchanged.
  • IC 50 value concentration of compound which inhibits to 50% the release of IL-1 ⁇
  • a LPS-suspension (Sigma, No. L-5886; 100 ⁇ g/5ml glucose solution/kg s.c.) is injected in male Tuttlingen SD rats
  • the ED 50 is the dose causing a 50% inhibition of the temperature increase determined in the control rats.
  • compounds of examples 40 and 50 have each an ED 50 value of 0.01 mg/kg p.o. and compound of example 51 an ED 50 value of 0.05 mg/kg p.o. Carrageenan-Induced Paw Edema in the Rat
  • test compound 50FA male rats, 150-170g body weight, are used for each group.
  • the test compound is administered orally as a suspension in physiological saline/0.5% tragacanth 1 hour prior to the carrageenan injection.
  • Carrageenan (0.1ml of a 1% suspension in physiological saline) is given by subplantar injection into one hind paw.
  • the swelling of the paw is measured by means of an antiphlogometer according to Kemper & Amelm.
  • a control reading is taken immediately after the injection, and the swelling is measured after 3 and 5 hrs.
  • the mean value of the 3- and 5-hour reading is taken after deduction of the control reading, the values obtained from the treated animals are expressed as a percentage of the value obtained from non-treated controls.
  • the ED 50 is the dose causing a 50% inhibition of the carrageenan-induced swelling after 3 hrs.
  • compounds of the invention inhibit significantly the carrageenen-induced swelling when administered p.o. at a dosage in the range of from 0.02 to 5 mg/kg. It has for example been determined that compound of example 40 and 50 have an ED 50 value of 0.2 and 1 mg/kg p.o. respectively.
  • Compounds of the invention are therefore useful for the treatment of disorders with an aetiology associated with or comprising excessive IL-1 ⁇ release, e.g. in a wide variety of inflammatory states and diseases, for example tissus calcium depletion, degenerative processes in bone and cartilage, e.g.
  • osteoporosis of various genesis including e.g. climacteric or post-menopausal osteoporosis as well as osteoporosis consequential to old age, immobilization or trauma, arteriosclerosis and Alzheimer disease.
  • the required dosage will of course vary depen ⁇ ding on the mode of administration, the particular condition to be treated and the effect desired. In general however, satisfactory results are achieved at daily dosage rates of from about 0.001 to about 100 mg/kg, preferably 0.001 to about 10 mg/kg animal body weight. Suitable daily dosage rates for larger mammals, for example humans, are of the order of from about 0.1 mg to about 1 g/day, conveniently administered once, in divided dosages 2 to 4 x/day, or in sustained release form.
  • the present invention also provides: a) A method for the treatment of disorders with an aetiology
  • a method comprises administering to said subject an effective amount of a compound of formula I, a physiologically-hydrolysable and -acceptable ester or amide thereof, or a pharmaceutically acceptable salt thereof; b) A compound of formula I, a physiologically-hydrolysable and -acceptable ester or amide thereof or a pharmaceutically acceptable salt thereof, for use as a pharmaceutical, for example for use as an agent, e.g. in the method as disclosed above.
  • the compounds of the invention may be administered by any con ⁇ ventional route, in particular nasally, enterally, preferably orally, e.g. in the form of tablets or capsules, or parenterally e.g. in the form of injectable solutions or suspensions or in a suppository form.
  • Unit dosage forms contain, for example from about 25 ⁇ g to 500 mg of a compound of the invention.
  • the compounds of the invention may be administered in free form or in pharmaceutically acceptable salt form.
  • Such salts may be prepared in conventional manner and exhibit the same order of activity as the free compounds.
  • compositions comprising a compound of formula I, a physiologically-hydrolysable and -acceptable ester or amide thereof or a pharmaceutically acceptable salt thereof, as hereinbefore defined, together with a pharmaceutically acceptable diluent or carrier therefor.
  • Such compositions may be manufactured in conventional manner. They may comprise up to 99.9% by weight of active ingredient.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Zoology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Toxicology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyridine Compounds (AREA)

Abstract

Di-, tri et tétrapeptides dans lesquels le dernier alpha-aminoacide est à base d'acide aspartique et accolé à un reste A5 qui représente H; CH3: -Z1-Z2-Y2, Z1 et Z2 représentant chacun indépendamment une liaison directe ou un reste d'alpha-aminoacide et Y2 représentant NH2, alkylamino C1-4, di-(alkyle C1-4) amino ou un radical hétérocyclique relié par un azote à Z2; -CH2-X1-Y3, X1 représentant O ou S et Y3 représentant hétéroaryle; -CH2-Y3; phényle substitué; phénylthiométhylène ou phénoxyméthylène à substitution de cycle; pyridyloxyméthylène à substitution de cycle; ou un radical -CH2-X1-CO-Y4, X1 représentant O ou S et Y4 représentant trialkylméthyle, ou phényle ou pyridyle substitué. Ces peptides, sous forme libre ou sous forme de sel, présentent une activité pharmacologique, par exemple, des propriétés d'inhibition de la libération d'IL-1beta.
EP92922580A 1991-11-04 1992-10-29 Peptides inhibant la liberation d'il-1 beta Withdrawn EP0611375A1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB919123326A GB9123326D0 (en) 1991-11-04 1991-11-04 Improvements in or relating to organic compounds
GB9123326 1991-11-04
PCT/EP1992/002472 WO1993009135A1 (fr) 1991-11-04 1992-10-29 Peptides inhibant la liberation d'il-1 beta

Publications (1)

Publication Number Publication Date
EP0611375A1 true EP0611375A1 (fr) 1994-08-24

Family

ID=10703998

Family Applications (1)

Application Number Title Priority Date Filing Date
EP92922580A Withdrawn EP0611375A1 (fr) 1991-11-04 1992-10-29 Peptides inhibant la liberation d'il-1 beta

Country Status (16)

Country Link
EP (1) EP0611375A1 (fr)
JP (1) JPH07500828A (fr)
AU (1) AU2885292A (fr)
CA (1) CA2116653A1 (fr)
CZ (1) CZ106794A3 (fr)
FI (1) FI942061A (fr)
GB (1) GB9123326D0 (fr)
HU (1) HUT68200A (fr)
IL (1) IL103612A0 (fr)
MX (1) MX9206306A (fr)
NO (1) NO941629L (fr)
NZ (1) NZ244985A (fr)
PT (1) PT101027A (fr)
SK (1) SK51194A3 (fr)
WO (1) WO1993009135A1 (fr)
ZA (1) ZA928511B (fr)

Families Citing this family (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5874424A (en) * 1995-12-20 1999-02-23 Vertex Pharmaceuticals Incorporated Inhibitors of interleukin-1β converting enzyme
US6008217A (en) * 1995-12-20 1999-12-28 Vertex Pharmaceuticals Incorporated Inhibitors of interleukin-1β converting enzyme
US6204261B1 (en) 1995-12-20 2001-03-20 Vertex Pharmaceuticals Incorporated Inhibitors of interleukin-1β Converting enzyme inhibitors
DE69226820T2 (de) * 1991-06-21 1999-05-12 Merck & Co., Inc., Rahway, N.J. Peptidylderivate als Inhibitoren von Interleukin-1B-konvertierenden Enzymen
EP0627926B1 (fr) * 1992-02-21 1998-08-05 Merck & Co., Inc. (a New Jersey corp.) DERIVES DE PEPTIDYLE UTILES COMME INHIBITEURS DE L'ENZYME CONVERTISSANT L'INTERLEUKINE-1$g(b)
EP0618223A3 (fr) * 1993-03-08 1996-06-12 Sandoz Ltd Peptides inhibent la libération d'interleukine 1-bêta utiles comme agents antiinflammatoires.
US5985838A (en) * 1993-04-29 1999-11-16 Vertex Pharmaceuticals, Inc. Peptide analogs as irreversible interleukin-1β protease inhibitors
TW494094B (en) * 1993-04-29 2002-07-11 Vertex Pharma Peptide analogs as irreversible interleukin-1β protease inhibitors and pharmaceutical compositions comprising the same
US5462939A (en) * 1993-05-07 1995-10-31 Sterling Winthrop Inc. Peptidic ketones as interleukin-1β-converting enzyme inhibitors
JPH0789951A (ja) * 1993-06-03 1995-04-04 Sterling Winthrop Inc インターロイキン−１β転換酵素阻害剤
US5843905A (en) * 1993-06-04 1998-12-01 Vertex Pharmaceuticals, Incorporated Peptidic phosphinyloxymethyl ketones as interleukin-1β-converting enzyme inhibitors
ATE170868T1 (de) * 1993-06-04 1998-09-15 Vertex Pharma Peptid-phosphinyloxymethyl-ketonen als inhibitoren von interleukin-1 beta- konvertierenden enzymen
AU7714594A (en) * 1993-08-13 1995-03-14 Merck & Co., Inc. Substituted ketone derivatives as inhibitors of interleukin-1beta converting enzyme
US5714484A (en) * 1993-12-08 1998-02-03 Prototek, Inc. α-(1,3-dicarbonylenol ether) methyl ketones as cysteine protease inhibitors
US5486623A (en) * 1993-12-08 1996-01-23 Prototek, Inc. Cysteine protease inhibitors containing heterocyclic leaving groups
US5552400A (en) * 1994-06-08 1996-09-03 Sterling Winthrop Inc. Fused-bicyclic lactams as interleukin-1β converting enzyme inhibitors
US6420522B1 (en) 1995-06-05 2002-07-16 Vertex Pharmaceuticals Incorporated Inhibitors of interleukin-1β converting enzyme
US5716929A (en) * 1994-06-17 1998-02-10 Vertex Pharmaceuticals, Inc. Inhibitors of interleukin-1β converting enzyme
US5847135A (en) * 1994-06-17 1998-12-08 Vertex Pharmaceuticals, Incorporated Inhibitors of interleukin-1β converting enzyme
US5756466A (en) * 1994-06-17 1998-05-26 Vertex Pharmaceuticals, Inc. Inhibitors of interleukin-1β converting enzyme
US5565430A (en) * 1994-08-02 1996-10-15 Sterling Winthrop Inc. Azaaspartic acid analogs as interleukin-1β converting enzyme inhibitors
GB2292149A (en) * 1994-08-09 1996-02-14 Ferring Res Ltd Peptide inhibitors of pro-interleukin-1beta converting enzyme
WO1996030395A2 (fr) * 1995-03-31 1996-10-03 Takeda Chemical Industries, Ltd. Inhibiteur de la protease de cysteine
US5798442A (en) * 1995-04-21 1998-08-25 Merck Frosst Canada, Inc. Peptidyl derivatives as inhibitors of pro-apoptotic cysteine proteinases
EP0761680A3 (fr) * 1995-09-12 1999-05-06 Ono Pharmaceutical Co., Ltd. Composés de tétrazole ayant une activité inhibante d'enzyme convertissant l'Interleukine-1bêta
US5843904A (en) * 1995-12-20 1998-12-01 Vertex Pharmaceuticals, Inc. Inhibitors of interleukin-1βconverting enzyme
EP0900791A1 (fr) * 1995-12-27 1999-03-10 Ono Pharmaceutical Co., Ltd. Derives de tetrazole et medicaments les contenant a titre d'ingredients actifs
US5869519A (en) * 1996-12-16 1999-02-09 Idun Pharmaceuticals, Inc. C-terminal modified (n-substituted)-2-indolyl dipeptides as inhibitors of the ICE/ced-3 family of cysteine proteases
US5968927A (en) * 1996-09-20 1999-10-19 Idun Pharmaceuticals, Inc. Tricyclic compounds for the inhibition of the ICE/ced-3 protease family of enzymes
US6184244B1 (en) * 1996-12-16 2001-02-06 Idun Pharmaceuticals, Inc. C-terminal modified (N-substituted)-2-indolyl dipeptides as inhibitors of the ICE/ced-3 family of cysteine proteases
US5877197A (en) * 1996-12-16 1999-03-02 Karanewsky; Donald S. C-terminal modified (N-substituted)-2-indolyl dipeptides as inhibitors of the ICE/ced-3 family of cysteine proteases
EP1011655A1 (fr) * 1997-02-26 2000-06-28 Ciblex Corporation Inhibiteurs d'exportation de proteine depourvue de sequence initiale
US6306613B1 (en) 1997-02-26 2001-10-23 Ciblex Corporation Modulators of leaderless protein export and methods for identifying and using the same
WO1999046248A1 (fr) 1998-03-09 1999-09-16 Vertex Pharmaceuticals Incorporated DERIVES DE LA 1,2-DIAZEPANE INHIBITEURS DE L'ENZYME DE CONVERSION DE L'INTERLEUKINE-1$g(b)
BR9909660A (pt) 1998-03-19 2000-11-21 Vertex Pharma Inibidores de caspases
US7157430B2 (en) 1998-10-22 2007-01-02 Idun Pharmaceuticals, Inc. (Substituted)acyl dipeptidyl inhibitors of the ICE/CED-3 family of cysteine proteases
US6242422B1 (en) 1998-10-22 2001-06-05 Idun Pharmacueticals, Inc. (Substituted)Acyl dipeptidyl inhibitors of the ice/ced-3 family of cysteine proteases
ATE363465T1 (de) * 1999-04-09 2007-06-15 Cytovia Inc Caspase inhibitoren und ihre verwendung
US6525024B1 (en) 2000-04-17 2003-02-25 Idun Pharmaceuticals, Inc. Inhibitors of the ICE/ced-3 family of cysteine proteases
EP1712239A3 (fr) 2000-05-12 2007-08-22 Immunex Corporation Inhibiteurs d'interleukine 1 dans le traitement de maladies
PE20011350A1 (es) 2000-05-19 2002-01-15 Vertex Pharma PROFARMACO DE UN INHIBIDOR DE ENZIMA CONVERTIDORA DE INTERLEUCINA-1ß (ICE)
PE20020500A1 (es) * 2000-09-13 2002-06-25 Vertex Pharma Derivados de piperidina, tetrahidroquinolina, tetrahidroisoquinolina como inhibidores de caspasas
WO2003075853A2 (fr) 2002-03-08 2003-09-18 Bristol-Myers Squibb Company Derives cycliques servant de modulateurs de l'activite du recepteur de la chimiokine
WO2005090334A2 (fr) 2004-03-12 2005-09-29 Vertex Pharmaceuticals Incorporated Procedes et produits intermediaires
US7531570B2 (en) 2004-05-27 2009-05-12 Vertex Pharmaceuticals Incorporated Treatment of diseases using ICE inhibitors
CN101979403A (zh) * 2010-09-13 2011-02-23 沈陵陵 新型半胱氨酸天冬氨酸广谱蛋白酶抑制剂及其制备方法和用途
WO2012061785A2 (fr) 2010-11-05 2012-05-10 Brandeis University Composés inhibiteurs de ice et leurs utilisations
US9956260B1 (en) 2011-07-22 2018-05-01 The J. David Gladstone Institutes Treatment of HIV-1 infection and AIDS
KR20180080311A (ko) 2015-11-13 2018-07-11 노파르티스 아게 신규 피라졸로 피리미딘 유도체

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1991015577A1 (fr) * 1990-04-04 1991-10-17 Black, Roy, A. INTERLEUKIN 1'beta' PROTEASE

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See references of WO9309135A1 *

Also Published As

Publication number Publication date
GB9123326D0 (en) 1991-12-18
IL103612A0 (en) 1993-04-04
FI942061A0 (fi) 1994-05-04
HUT68200A (en) 1995-05-29
PT101027A (pt) 1994-02-28
JPH07500828A (ja) 1995-01-26
NZ244985A (en) 1995-06-27
CA2116653A1 (fr) 1993-05-13
NO941629D0 (no) 1994-05-03
SK51194A3 (en) 1995-02-08
ZA928511B (en) 1994-05-04
MX9206306A (es) 1993-05-01
WO1993009135A1 (fr) 1993-05-13
NO941629L (no) 1994-07-04
HU9401303D0 (en) 1994-08-29
FI942061A (fi) 1994-05-04
AU2885292A (en) 1993-06-07
CZ106794A3 (en) 1994-12-15

Similar Documents

Publication Publication Date Title
EP0611375A1 (fr) Peptides inhibant la liberation d'il-1 beta
US4918105A (en) Novel compounds with collagenase-inhibiting activity, a process for their preparation and pharmaceutical compositions in which these compounds are present
JP4173536B2 (ja) インターロイキン−１β変換酵素の二環式ラクタム阻害剤
KR890003602B1 (ko) 옥사-및 아자호모사이클로스타틴 폴리펩티드의 제조방법
US4743587A (en) Hydroxamic acid based collagenase inhibitors
DE69427557T2 (de) Peptide-Analoge mit irreversibler Interleukin-1 Beta-Protease Inhibitoren
EP0618223A2 (fr) Peptides inhibent la libération d'interleukine 1-bêta utiles comme agents antiinflammatoires
WO1989007610A1 (fr) INHIBITEUR DE RENINE CONTENANT DES AMINOACIDES AVEC UN HETEROATOME alpha
JPS62230757A (ja) ヒドロキシルアミン誘導体
JPH07179414A (ja) サイトカイン生成を誘発するウレタン類およびウレア類
EP0200406A2 (fr) Dérivés d'amino-acides
AU599367B2 (en) Novel amino acid derivatives
US4382889A (en) Epoxysuccinic acid derivatives
US4297275A (en) Inhibitors of mammalian collagenase
EP0190891A2 (fr) Dérivés d'acides aminés
US4322436A (en) Novel substituted phenylacetic acid amide compounds
US4420490A (en) Substituted phenylacetic acid amide compounds
US4250192A (en) Novel substituted phenylacetic acid amide compounds
US5985838A (en) Peptide analogs as irreversible interleukin-1β protease inhibitors
US5166154A (en) Imidazo[1,2-a]piperazines
JPH0647599B2 (ja) ヘプタノイル―Ｇｌｕ―Ａｓｐ―Ａｌａ―アミノ酸系免疫賦活薬
CA1298307C (fr) Inhibiteurs de l'encephalinase
US4247543A (en) Organic compounds
US4853463A (en) Amino acid derivatives
HU188177B (en) Process for producing new proline derivatives

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 19940319

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LI LU NL SE

17Q First examination report despatched

Effective date: 19951005

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 19960216